methyl 2-((3,4-dihydro-3,4-dioxo-1-naphthalenyl)amino)benzoate has been researched along with dinoprost in 1 studies
| Studies (methyl 2-((3,4-dihydro-3,4-dioxo-1-naphthalenyl)amino)benzoate) | Trials (methyl 2-((3,4-dihydro-3,4-dioxo-1-naphthalenyl)amino)benzoate) | Recent Studies (post-2010) (methyl 2-((3,4-dihydro-3,4-dioxo-1-naphthalenyl)amino)benzoate) | Studies (dinoprost) | Trials (dinoprost) | Recent Studies (post-2010) (dinoprost) |
|---|---|---|---|---|---|
| 16 | 0 | 0 | 11,554 | 940 | 1,936 |
| Protein | Taxonomy | methyl 2-((3,4-dihydro-3,4-dioxo-1-naphthalenyl)amino)benzoate (IC50) | dinoprost (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 0.0025 | |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.0713 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 0.14 | |
| Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | 0.3 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.14 | |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | 4.2 | |
| Prostaglandin F2-alpha receptor | Bos taurus (cattle) | 0.14 | |
| Prostaglandin F2-alpha receptor | Homo sapiens (human) | 0.0139 | |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | 0.216 | |
| Prostaglandin D2 receptor | Homo sapiens (human) | 4.5 | |
| Solute carrier organic anion transporter family member 2B1 | Rattus norvegicus (Norway rat) | 0.287 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kruse-Elliott, KT; Olson, NC | 1 |
1 other study(ies) available for methyl 2-((3,4-dihydro-3,4-dioxo-1-naphthalenyl)amino)benzoate and dinoprost
| Article | Year |
|---|---|
CGS 8515 and indomethacin attenuate cytokine-induced cardiopulmonary dysfunction in pigs.
Topics: 6-Ketoprostaglandin F1 alpha; Albumins; Animals; Arachidonic Acids; Bronchoalveolar Lavage Fluid; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Cytokines; Dinoprost; Drug Synergism; Eicosanoids; Heart; Heart Diseases; Hydroxyeicosatetraenoic Acids; Indomethacin; Injections, Intravenous; Interleukin-1; Leukotriene B4; Lipoxygenase Inhibitors; Lung; Lung Diseases; Naphthoquinones; ortho-Aminobenzoates; Swine; Thromboxane B2; Tumor Necrosis Factor-alpha; Vascular Resistance | 1993 |